Phase 1b/2a Safety and Tolerability Study of Bemcentinib With Pembrolizumab/Carboplatin/Pemetrexed in Subjects With Untreated Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Without/With a STK11 Mutation

The primary purpose of this study is to determine the safety and tolerability of the combination of bemcentinib with chemo-immunotherapy (CIT) to identify the recommended phase 2 dose (RP2D) when administered as first line (1L) treatment in participants with locally advanced (Stage IIIb/IIIC) or metastatic (Stage IV) non-squamous NSCLC with no actionable mutations and to determine the anti-tumor activity of the combination of bemcentinib with CIT when administered as 1L treatment in participants with locally advanced (Stage IIIb/IIIc) or metastatic (Stage IV) non-squamous NSCLC with serine/threonine kinase 11 (STK11) mutation and no actionable mutations.

Start Date14 Dec 2022

Sponsor / Collaborator

BerGenBio ASA

NCT06469138 / CompletedPhase 1

A Phase 1, Open-label, Nonrandomized Study to Investigate the Mass Balance Recovery and Metabolic Profile of 14C-bemcentinib Following Single Oral Administration in Healthy Male Subjects

The aims of this Study are to determine:
How much of the Study Drug (bemcentinib) ends up in urine and faeces
How much of the Study Drug and its breakdown products get into the bloodstream
The breakdown products (metabolites) of the Study Drug
The safety of the Study Drug and any side effects that might be associated with it.

Start Date02 Aug 2022

Sponsor / Collaborator

BerGenBio ASA

CTIS2022-500363-12-00 / Not yet recruiting

Efficacy and Safety of AXL-Inhibitor bemcentinib for the Treatment of Moderate COVID-19 (AXL-SolidAct) - AXL-SolidAct

Start Date05 Jul 2022

Sponsor / Collaborator-

100 Clinical Results associated with Bemcentinib

100 Translational Medicine associated with Bemcentinib

100 Patents (Medical) associated with Bemcentinib

129

Literatures (Medical) associated with Bemcentinib

08 Mar 2024·JCI insight

AXL inhibition suppresses early allograft monocyte-to-macrophage differentiation and prolongs allograft survival.

Article

Author: Souma, Tomokazu ; Xiang, Catherine ; Kwun, Jean ; Dilts, Miriam E ; Jordan, Collin Z ; Tunbridge, Matthew ; Thorp, Edward B ; Husain, Irma ; Kitai, Hiroki ; Abe, Koki ; Luo, Xunrong ; Fay, Olivia K

Innate immune cells are important in the initiation and potentiation of alloimmunity in transplantation. Immediately upon organ anastomosis and reperfusion, recipient monocytes enter the graft from circulation and differentiate to inflammatory macrophages to promote allograft inflammation. However, factors that drive their differentiation to inflammatory macrophages are not understood. Here, we show that the receptor tyrosine kinase AXL was a key driver of early intragraft differentiation of recipient infiltrating monocytes to inflammatory macrophages in the presence of allogeneic stimulation and cell-to-cell contact. In this context, the differentiated inflammatory macrophages were capable of efficient alloantigen presentation and allostimulation of T cells of the indirect pathway. Consequently, early and transient AXL inhibition with the pharmacological inhibitor bemcentinib resulted in a profound reduction of initial allograft inflammation and a significant prolongation of allograft survival in a murine heart transplant model. Our results support further investigation of AXL inhibition as part of an induction regimen for transplantation.

01 Dec 2023·Acta pharmaceutica Sinica. B

Structure-based drug discovery of novel fused-pyrazolone carboxamide derivatives as potent and selective AXL inhibitors

Article

Author: Liu, Hong ; Geng, Meiyu ; Liang, Xuewu ; Zhang, Dong ; Fang, Feifei ; Wang, Danyi ; Ai, Jing ; Li, Chunpu ; Ji, Yinchun ; Peng, Xia ; Li, Yazhou ; Wang, Hao ; Zhou, Yu ; Li, Jiyuan ; Zhang, Dan ; Dai, Yang ; Zhao, Yangrong

As a novel and promising antitumor target, AXL plays an important role in tumor growth, metastasis, immunosuppression and drug resistance of various malignancies, which has attracted extensive research interest in recent years. In this study, by employing the structure-based drug design and bioisosterism strategies, we designed and synthesized in total 54 novel AXL inhibitors featuring a fused-pyrazolone carboxamide scaffold, of which up to 20 compounds exhibited excellent AXL kinase and BaF3/TEL-AXL cell viability inhibitions. Notably, compound 59 showed a desirable AXL kinase inhibitory activity (IC₅₀: 3.5 nmol/L) as well as good kinase selectivity, and it effectively blocked the cellular AXL signaling. In turn, compound 59 could potently inhibit BaF3/TEL-AXL cell viability (IC₅₀: 1.5 nmol/L) and significantly suppress GAS6/AXL-mediated cancer cell invasion, migration and wound healing at the nanomolar level. More importantly, compound 59 oral administration showed good pharmacokinetic profile and in vivo antitumor efficiency, in which we observed significant AXL phosphorylation suppression, and its antitumor efficacy at 20 mg/kg (qd) was comparable to that of BGB324 at 50 mg/kg (bid), the most advanced AXL inhibitor. Taken together, this work provided a valuable lead compound as a potential AXL inhibitor for the further antitumor drug development.

01 Dec 2023·Journal, genetic engineering & biotechnology

Pangenome diversification and resistance gene characterization in Salmonella Typhi prioritized RfaJ as a significant therapeutic marker

Article

Author: Jalal, Khurshid ; Khan, Kanwal ; Uddin, Reaz

Abstract:

Background:

Salmonella Typhi stands as the etiological agent responsible for the onset of human typhoid fever. The pressing demand for innovative therapeutic targets against S. Typhi is underscored by the escalating prevalence of this pathogen and the severe nature of its infections. Consequently, this study employs pangenome analysis to scrutinize 119 S. Typhi-resistant strains, aiming to identify the most promising therapeutic targets originating from its core genome.

Results:

Subtractive genomics was employed to systematically eliminate non-homologous (n=1147), essential (n=551), drug-like (n=80), and pathogenicity-related (n=18) proteins from the initial pool of 3351 core genome proteins. Consequently, lipopolysaccharide 1,2-glucosyltransferase RfaJ was designated as the optimal pharmacological target due to its potential versatility. Furthermore, a compendium of 9000 FDA-approved compounds was repurposed for evaluation against the RfaJ drug target, with the specific intent of prioritizing novel, high-potency therapeutic candidates for combating S. Typhi. Ultimately, four compounds, namely DB00549 (Zafirlukast), DB15637 (Fluzoparib), DB15688 (Zavegepant), and DB12411 (Bemcentinib), were singled out as potential inhibitors based on the ligand-protein binding affinity (indicated by the lowest anticipated binding energy) and the overall stability of these compounds. Notably, molecular dynamics simulations, conducted over a 50 nanosecond interval, convincingly demonstrated the stability of these compounds in the context of the RfaJ protein.

Conclusion:

In summary, the present findings hold significant promise as an initial stride in the broader drug discovery endeavor against S. Typhi infections. However, the experimental validation of the identified drug target and drug candidate is further required to increase the effectiveness of the applied methodology.

News (Medical) associated with Bemcentinib

29 May 2024

·www.prnewswire.com

BerGenBio First Quarter Results 2024: Advancing to the Next Stage of Development

BERGEN, Norway, May 29, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage bio-pharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter ended March 31, 2024, and provided a business update. Highlights, including post period: Data Safety Monitoring Board review supported dose escalation in Ph 1b and initiation of Ph2a Site activation of Ph2a in US and Europe proceeding well Bemcentinib remains the leading selective AXL inhibitor in the clinic and was selected for inclusion in National Cancer Institute funded study in advanced NSCLC, led by the Mays Cancer Center at the University of Texas Health Science Center at San Antonio Financial position of NOK 117.3 million at 31 March – strengthened further with gross funding of NOK 138.9 million from warrants exercise in April 2024 Continued reduction of operating expenses from NOK 72.4 million in Q1 2023 to NOK 39.9 million in Q1 2024 Net cash flow of NOK -42.5 million Martin Olin, Chief Executive Officer of BerGenBio stated: "1L NSCLC STK11m patients are not currently eligible for targeted therapy and face a very poor prognosis. The total market for this patient group is estimated to be between 4 and 5 billion USD. The initiation of Phase 2a of the study of our lead compound bemcentinib in these patients represents an important milestone for the company. Our clinical progress in the quarter combined with the successful capital raise from the warrants exercise positions BerGenBio to advance a new much needed therapeutic option for these patients with high unmet medical need." Presentation and Financial Report The Q1 2024 Financial report is attached to this stock exchange announcement and the report and the Q1 2024 presentation are available at the Company's website . Webcast details BerGenBio's senior management team will provide a business update today at 10:00 am CET. The presentation will webcast live. To participate in the webcast, please use the following link: A recording of the webcast will be available at in the Investors/Financial Reports section () shortly afterwards. Contacts Martin Olin CEO, BerGenBio ASA [email protected] Rune Skeie, CFO, BerGenBio ASA [email protected] Media Relations Jan Lilleby [email protected] About BerGenBio ASA BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate, bemcentinib, a potentially first-in-class selective AXL inhibitor in clinical development for STK11 mutated NSCLC and preclinical development for severe respiratory infections. BerGenBio is based in Bergen, Norway, with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit Forward looking statements This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. This information is considered to be inside information pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. This information was brought to you by Cision The following files are available for download: SOURCE BerGenBio ASA

Financial StatementPhase 2

28 May 2024

·www.prnewswire.com

BerGenBio Announces NCI Clinical Collaboration with UT Health San Antonio and Sobi®

BERGEN, Norway, May 28, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today that it has entered into a clinical trial agreement with the Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) and Swedish Orphan Biovitrum AB (Sobi®) (STO:SOBI), a specialized international biopharmaceutical company. The parties will collaborate to study BerGenBio's selective AXL inhibitor, bemcentinib, in combination with Sobi's pacritinib in patients with advanced lung adenocarcinoma. The clinical study is externally funded and is complementary to BerGenBio's ongoing Ph1b/2a clinical study in first-line Non-Small Cell Lung Cancer patients with mutations in the STK11 gene. Bemcentinib is a first-in-class, selective, oral once-a-day inhibitor of AXL receptor tyrosine kinase, a promising therapeutic target for serious diseases. Pacritinib (marketed as VONJO®) is a JAK2 inhibitor indicated for treatment of myelofibrosis, a bone marrow disorder, and works by blocking certain growth factors and cytokines. The clinical study will advance the ground-breaking work of Josephine A. Taverna, MD, a thoracic oncologist at the Mays Cancer Center and Assistant Professor in the Division of Hematology and Oncology at UT Health San Antonio. Dr. Taverna's prior research has demonstrated that AXL and JAK-STAT3 work together to transmit signals that promote tumor growth and metastasis in advanced lung cancer. The study will be performed in collaboration with Sobi® and will be led by Dr. Taverna as the principal investigator and is funded by a grant received from the National Cancer Institute (NCI) of the National Institutes of Health (NIH). Martin Olin, Chief Executive Officer of BerGenBio stated, "We are excited to work with two stellar partners to bring this intriguing area of research to patients. This study will further extend our knowledge of the role of selective AXL inhibition with bemcentinib in lung cancer, our area of highest strategic focus." Dr. Taverna commented, "Our data suggests that targeting the AXL-STAT3 pathway with bemcentinib and pacritinib can prevent tumor cells from recruiting tumor-associated macrophages and other aggressive host cells into the tumor microenvironment, disrupting tumor growth and metastatic spread. Understanding this discovery could shed light on novel therapeutic strategies for lung cancer." Contacts Martin Olin CEO, BerGenBio ASA [email protected] Rune Skeie, CFO, BerGenBio ASA [email protected] Investor Relations / Media Relations Jan Lilleby [email protected] About BerGenBio ASA BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate, bemcentinib, a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections. BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit About Mays Cancer Center at UT Health San Antonio The Mays Cancer Center at UT Health San Antonio is one of only four National Cancer Institute-designated Cancer Centers in Texas. The Mays Cancer Center provides leading-edge cancer care, propels innovative cancer research and educates the next generation of leaders to end cancer in South Texas. To learn more, visit . Stay connected with the Mays Cancer Center on Facebook, Twitter, LinkedIn, Instagram and YouTube. About The University of Texas Health Science Center at San Antonio The University of Texas Health Science Center at San Antonio (UT Health San Antonio) is one of the country's leading health science universities and is designated as a Hispanic-Serving Institution by the U.S. Department of Education. With missions of teaching, research, patient care and community engagement, its schools of medicine, nursing, dentistry, health professions, graduate biomedical sciences and public health have graduated more than 42,550 alumni who are leading change, advancing their fields and renewing hope for patients and their families throughout South Texas and the world. To learn about the many ways "We make lives better®," visit UTHealthSA.org. Stay connected with The University of Texas Health Science Center at San Antonio on Facebook, Twitter, LinkedIn, Instagram and YouTube. Forward looking statements This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. This information was brought to you by Cision

Clinical Study

09 Apr 2024

·www.pharmaceutical-technology.com

Basilea wins CARB-X grant for new antibody development

Basilea may receive additional funding from CARB-X for further preclinical and early clinical development, contingent on certain undisclosed project milestones, as per the company. Image Credit: Marian Weyo / Shutterstock. Switzerland-based Basilea Pharmaceutica has received a $0.9m grant from the global non-profit, Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), to develop a new antibiotic. Free Whitepaper PepSetsTM and their Applications Peptide libraries are a powerful tool in biological research for screening large numbers of peptides in the search for the few, critical bioactive peptides. Mimotopes PepSets are custom-synthesized peptide libraries supplied unpuried for fast, efcient screening work. These sets of chemically synthesized individual peptides are made on a small scale using Mimotopes’ unique proprietary parallel array synthesis platform. PepSets comprising hundreds, or even thousands of peptides, are rapidly synthesized and shipped within a few weeks of ordering. Submit Country Code * UK (+44) USA (+1) Algeria (+213) Andorra (+376) Angola (+244) Anguilla (+1264) Antigua & Barbuda (+1268) Argentina (+54) Armenia (+374) Aruba (+297) Australia (+61) Austria (+43) Azerbaijan (+994) Bahamas (+1242) Bahrain (+973) Bangladesh (+880) Barbados (+1246) Belarus (+375) Belgium (+32) Belize (+501) Benin (+229) Bermuda (+1441) Bhutan (+975) Bolivia (+591) Bosnia Herzegovina (+387) Botswana (+267) Brazil (+55) Brunei (+673) Bulgaria (+359) Burkina Faso (+226) Burundi (+257) Cambodia (+855) Cameroon (+237) Canada (+1) Cape Verde Islands (+238) Cayman Islands (+1345) Central African Republic (+236) Chile (+56) China (+86) Colombia (+57) Comoros (+269) Congo (+242) Cook Islands (+682) Costa Rica (+506) Croatia (+385) Cuba (+53) Cyprus North (+90392) Cyprus South (+357) Czech Republic (+42) Denmark (+45) Djibouti (+253) Dominica (+1809) Dominican Republic (+1809) Ecuador (+593) Egypt (+20) El Salvador (+503) Equatorial Guinea (+240) Eritrea (+291) Estonia (+372) Ethiopia (+251) Falkland Islands (+500) Faroe Islands (+298) Fiji (+679) Finland (+358) France (+33) French Guiana (+594) French Polynesia (+689) Gabon (+241) Gambia (+220) Georgia (+7880) Germany (+49) Ghana (+233) Gibraltar (+350) Greece (+30) Greenland (+299) Grenada (+1473) Guadeloupe (+590) Guam (+671) Guatemala (+502) Guinea (+224) Guinea - Bissau (+245) Guyana (+592) Haiti (+509) Honduras (+504) Hong Kong (+852) Hungary (+36) Iceland (+354) India (+91) Indonesia (+62) Iran (+98) Iraq (+964) Ireland (+353) Israel (+972) Italy (+39) Jamaica (+1876) Japan (+81) Jordan (+962) Kazakhstan (+7) Kenya (+254) Kiribati (+686) Korea North (+850) Korea South (+82) Kuwait (+965) Kyrgyzstan (+996) Laos (+856) Latvia (+371) Lebanon (+961) Lesotho (+266) Liberia (+231) Libya (+218) Liechtenstein (+417) Lithuania (+370) Luxembourg (+352) Macao (+853) Macedonia (+389) Madagascar (+261) Malawi (+265) Malaysia (+60) Maldives (+960) Mali (+223) Malta (+356) Marshall Islands (+692) Martinique (+596) Mauritania (+222) Mayotte (+269) Mexico (+52) Micronesia (+691) Moldova (+373) Monaco (+377) Mongolia (+976) Montserrat (+1664) Morocco (+212) Mozambique (+258) Myanmar (+95) Namibia (+264) Nauru (+674) Nepal (+977) Netherlands (+31) New Caledonia (+687) New Zealand (+64) Nicaragua (+505) Niger (+227) Nigeria (+234) Niue (+683) Norfolk Islands (+672) Northern Marianas (+670) Norway (+47) Oman (+968) Palau (+680) Panama (+507) Papua New Guinea (+675) Paraguay (+595) Peru (+51) Philippines (+63) Poland (+48) Portugal (+351) Puerto Rico (+1787) Qatar (+974) Reunion (+262) Romania (+40) Russia (+7) Rwanda (+250) San Marino (+378) Sao Tome & Principe (+239) Saudi Arabia (+966) Senegal (+221) Serbia (+381) Seychelles (+248) Sierra Leone (+232) Singapore (+65) Slovak Republic (+421) Slovenia (+386) Solomon Islands (+677) Somalia (+252) South Africa (+27) Spain (+34) Sri Lanka (+94) St. Helena (+290) St. Kitts (+1869) St. Lucia (+1758) Sudan (+249) Suriname (+597) Swaziland (+268) Sweden (+46) Switzerland (+41) Syria (+963) Taiwan (+886) Tajikstan (+7) Thailand (+66) Togo (+228) Tonga (+676) Trinidad & Tobago (+1868) Tunisia (+216) Turkey (+90) Turkmenistan (+7) Turkmenistan (+993) Turks & Caicos Islands (+1649) Tuvalu (+688) Uganda (+256) Ukraine (+380) United Arab Emirates (+971) Uruguay (+598) Uzbekistan (+7) Vanuatu (+678) Vatican City (+379) Venezuela (+58) Vietnam (+84) Virgin Islands - British (+1284) Virgin Islands - US (+1340) Wallis & Futuna (+681) Yemen (North)(+969) Yemen (South)(+967) Zambia (+260) Zimbabwe (+263) Country * UK USA Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo Democratic Republic of the Congo Cook Islands Costa Rica Côte d"Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Lao Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Réunion Romania Russian Federation Rwanda Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates US Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam British Virgin Islands US Virgin Islands Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Kosovo By downloading this case study, you acknowledge that GlobalData may share your information with Mimotopes Thematic and that your personal data will be used as described in their Privacy Policy Submit Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address. Thank you. You will receive an email shortly. Please check for download the Whitepaper. Go deeper with GlobalData Reports LOA and PTSR Model - Bemcentinib in Refractory Acute Myeloid Leukemia Reports LOA and PTSR Model - Briquilimab in Beta Thalassaemia Premium Insights The gold standard of business intelligence. Find out more The grant will fund the preclinical development of an antibiotic candidate until the candidate’s nomination, which is expected in H2 this year. Basilea added that the company may receive additional funding from CARB-X for further preclinical and early clinical development, contingent on certain undisclosed project milestones. The antibiotic programme that received funding was developed using the Spexis’ outer membrane protein targeting antibiotics (OMPTA) technology, which Basilea acquired in January . The OMPTA class of antibiotics binds dually to lipopolysaccharide and outer-membrane proteins. These proteins provide structural integrity and a permeability barrier to protect the gram-negative bacterial cell. Therefore, any disruption in the function of these proteins can cause the bacteria to die. See Also: Prothea debuts with $13m to develop cancer diagnostics and treatment Medicxi and Starpharma to develop dendrimer-based cancer treatments The CARB-X’s funding is provided through the US Biomedical Advanced Research and Development Authority (BARDA) ’s antibacterial branch. Basilea has previously received funds from the US Government to develop its portfolio of antibacterials and antifungals. The company’s recently approved antibiotic Zevtera (ceftobiprole) was developed through subsidised funding from BARDA . Antimicrobial resistance (AMR) has become a growing issue in recent years, with the World Health Organisation (WHO) declaring it one of the top global public health and development threats. The US bacterial infection market is expected to be worth $4.1bn by 2024, according to GlobalData . GlobalData is the parent company of Pharmaceutical Technology . In light of the growing demand, there has been an increased interest in developing new therapies to combat this issue. In September 2023, Novo Holdings acquired Boston-based Paratek Pharmaceuticals to bolster its AMR expertise. Paratek’s portfolio consisted of Nuzyra (omadacycline), a marketed once-a-day oral and intravenous antibiotic indicated for acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). Another antibiotic currently in development is Roche’s zosurabalpin. It is classified under a new antibiotic class of drugs called tethered macrocyclic peptides. Zosurabalpin targets the lipopolysaccharide (LPS) transport systems, which is important for maintaining bacterial cell structure among other functions. Early R&D project coverage on Pharmaceutical Technology is supported by Mimotopes. Editorial content is independently produced and follows highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. Free Whitepaper PepSetsTM and their Applications Peptide libraries are a powerful tool in biological research for screening large numbers of peptides in the search for the few, critical bioactive peptides. Mimotopes PepSets are custom-synthesized peptide libraries supplied unpuried for fast, efcient screening work. These sets of chemically synthesized individual peptides are made on a small scale using Mimotopes’ unique proprietary parallel array synthesis platform. PepSets comprising hundreds, or even thousands of peptides, are rapidly synthesized and shipped within a few weeks of ordering. By Mimotopes Thematic Submit Country Code * UK (+44) USA (+1) Algeria (+213) Andorra (+376) Angola (+244) Anguilla (+1264) Antigua & Barbuda (+1268) Argentina (+54) Armenia (+374) Aruba (+297) Australia (+61) Austria (+43) Azerbaijan (+994) Bahamas (+1242) Bahrain (+973) Bangladesh (+880) Barbados (+1246) Belarus (+375) Belgium (+32) Belize (+501) Benin (+229) Bermuda (+1441) Bhutan (+975) Bolivia (+591) Bosnia Herzegovina (+387) Botswana (+267) Brazil (+55) Brunei (+673) Bulgaria (+359) Burkina Faso (+226) Burundi (+257) Cambodia (+855) Cameroon (+237) Canada (+1) Cape Verde Islands (+238) Cayman Islands (+1345) Central African Republic (+236) Chile (+56) China (+86) Colombia (+57) Comoros (+269) Congo (+242) Cook Islands (+682) Costa Rica (+506) Croatia (+385) Cuba (+53) Cyprus North (+90392) Cyprus South (+357) Czech Republic (+42) Denmark (+45) Djibouti (+253) Dominica (+1809) Dominican Republic (+1809) Ecuador (+593) Egypt (+20) El Salvador (+503) Equatorial Guinea (+240) Eritrea (+291) Estonia (+372) Ethiopia (+251) Falkland Islands (+500) Faroe Islands (+298) Fiji (+679) Finland (+358) France (+33) French Guiana (+594) French Polynesia (+689) Gabon (+241) Gambia (+220) Georgia (+7880) Germany (+49) Ghana (+233) Gibraltar (+350) Greece (+30) Greenland (+299) Grenada (+1473) Guadeloupe (+590) Guam (+671) Guatemala (+502) Guinea (+224) Guinea - Bissau (+245) Guyana (+592) Haiti (+509) Honduras (+504) Hong Kong (+852) Hungary (+36) Iceland (+354) India (+91) Indonesia (+62) Iran (+98) Iraq (+964) Ireland (+353) Israel (+972) Italy (+39) Jamaica (+1876) Japan (+81) Jordan (+962) Kazakhstan (+7) Kenya (+254) Kiribati (+686) Korea North (+850) Korea South (+82) Kuwait (+965) Kyrgyzstan (+996) Laos (+856) Latvia (+371) Lebanon (+961) Lesotho (+266) Liberia (+231) Libya (+218) Liechtenstein (+417) Lithuania (+370) Luxembourg (+352) Macao (+853) Macedonia (+389) Madagascar (+261) Malawi (+265) Malaysia (+60) Maldives (+960) Mali (+223) Malta (+356) Marshall Islands (+692) Martinique (+596) Mauritania (+222) Mayotte (+269) Mexico (+52) Micronesia (+691) Moldova (+373) Monaco (+377) Mongolia (+976) Montserrat (+1664) Morocco (+212) Mozambique (+258) Myanmar (+95) Namibia (+264) Nauru (+674) Nepal (+977) Netherlands (+31) New Caledonia (+687) New Zealand (+64) Nicaragua (+505) Niger (+227) Nigeria (+234) Niue (+683) Norfolk Islands (+672) Northern Marianas (+670) Norway (+47) Oman (+968) Palau (+680) Panama (+507) Papua New Guinea (+675) Paraguay (+595) Peru (+51) Philippines (+63) Poland (+48) Portugal (+351) Puerto Rico (+1787) Qatar (+974) Reunion (+262) Romania (+40) Russia (+7) Rwanda (+250) San Marino (+378) Sao Tome & Principe (+239) Saudi Arabia (+966) Senegal (+221) Serbia (+381) Seychelles (+248) Sierra Leone (+232) Singapore (+65) Slovak Republic (+421) Slovenia (+386) Solomon Islands (+677) Somalia (+252) South Africa (+27) Spain (+34) Sri Lanka (+94) St. Helena (+290) St. Kitts (+1869) St. Lucia (+1758) Sudan (+249) Suriname (+597) Swaziland (+268) Sweden (+46) Switzerland (+41) Syria (+963) Taiwan (+886) Tajikstan (+7) Thailand (+66) Togo (+228) Tonga (+676) Trinidad & Tobago (+1868) Tunisia (+216) Turkey (+90) Turkmenistan (+7) Turkmenistan (+993) Turks & Caicos Islands (+1649) Tuvalu (+688) Uganda (+256) Ukraine (+380) United Arab Emirates (+971) Uruguay (+598) Uzbekistan (+7) Vanuatu (+678) Vatican City (+379) Venezuela (+58) Vietnam (+84) Virgin Islands - British (+1284) Virgin Islands - US (+1340) Wallis & Futuna (+681) Yemen (North)(+969) Yemen (South)(+967) Zambia (+260) Zimbabwe (+263) Country * UK USA Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo Democratic Republic of the Congo Cook Islands Costa Rica Côte d"Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Lao Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Réunion Romania Russian Federation Rwanda Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates US Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam British Virgin Islands US Virgin Islands Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Kosovo By downloading this case study, you acknowledge that GlobalData may share your information with Mimotopes Thematic and that your personal data will be used as described in their Privacy Policy Submit Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address. Thank you. You will receive an email shortly. Please check for download the Whitepaper.

AcquisitionDrug Approval

100 Deals associated with Bemcentinib

External Link

KEGG	Wiki	ATC	Drug Bank
D11438	Bemcentinib	-	DB12411

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 3	NO	BerGenBio ASA	-
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma	Phase 2	US	BerGenBio ASA	14 Dec 2022
Secondary malignant neoplasm of pancreas	Phase 2	US	BerGenBio ASA	03 Jan 2019
High Risk Myelodysplastic Syndrome	Phase 2	FR	BerGenBio ASA	20 Dec 2018
High Risk Myelodysplastic Syndrome	Phase 2	DE	BerGenBio ASA	20 Dec 2018
High Risk Myelodysplastic Syndrome	Phase 2	NL	BerGenBio ASA	20 Dec 2018
Advanced Lung Adenocarcinoma	Phase 2	US	BerGenBio ASA	17 Oct 2017
Advanced Lung Adenocarcinoma	Phase 2	NO	BerGenBio ASA	17 Oct 2017
Advanced Lung Adenocarcinoma	Phase 2	ES	BerGenBio ASA	17 Oct 2017
Advanced Lung Adenocarcinoma	Phase 2	GB	BerGenBio ASA	17 Oct 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2023	Phase 1/2	Acute Myeloid Leukemia \| Myelodysplastic Syndromes	86	Bemcentinib Monotherapy	ukzhehiyzn(qoxtqyuktr) = ntzdzrhgpp jrlougzatk (iwetwfhqdh ) View more	-	11 Dec 2023
				Bemcentinib + Cytarabine	ukzhehiyzn(qoxtqyuktr) = axaqdrczyc jrlougzatk (iwetwfhqdh ) View more
NCT02488408 (BGBC003, ASH2023)	Phase 1/2	Acute Myeloid Leukemia	32	Bemcentinib + Low-dose Cytarabine	wtbjnpdmki(vawuapjjmv) = ldjkhguikz qequbvhxph (zdbnmexsgx ) View more	-	09 Dec 2023
NCT03649321 (CTgov)	Phase 1/2	Secondary malignant neoplasm of pancreas	9	Nab-paclitaxel+gemcitabine+cisplatin+Bemcentinib (Phase 1b)	bkedhckbtm(qtzhwgowrv) = idbemjpvmt ktlhlnsdgx (krlhglgtkt, pycydlmktx - onlwegymbw) View more	-	09 Nov 2023
				Nab-paclitaxel+gemcitabine+Bemcentinib (Phase 2)	bkedhckbtm(qtzhwgowrv) = zpevbbhyek ktlhlnsdgx (krlhglgtkt, lgtrlwmqgn - vzmuselfrb) View more
NCT03184571 (BGBC008, ESMO2023) Manual	Phase 2	Non-Small Cell Lung Cancer Second line	99	Bemcentinib + Pembrolizumab	nykdedlvqn(hgrrfywewa) = ekdurdhxtp aazciagfde (gmznnpregv ) View more	Positive	23 Oct 2023
				Bemcentinib + Pembrolizumab (AXL TPS > 5)	nykdedlvqn(hgrrfywewa) = pvpfbwcwuw aazciagfde (gmznnpregv ) View more
NCT02872259 (BGBIL006, ESMO2023) Manual	Phase 1/2	Metastatic melanoma	68	Bemcentinib+Pem or D/T (Bemcentinib+Pembrolizumab or Dabrafenib/Trametinib)	dwcqnzruun(cejwgxqdya) = cnnarleyva rvyuvsqwvi (hefjmsplqv ) View more	Negative	21 Oct 2023
				Pem or D/T (Pembrolizumab or Dabrafenib/Trametinib)	-
NCT03654833 (MiST3, ASCO2023) Manual	Phase 2	Mesothelioma	26	Pembrolizumab+Bemcentinib	xethioswqs(yxzetylurh) = uaewhuhtui thxstzquko (orqlfzozsm, 29.2 - 63.4) View more	Positive	26 May 2023
NCT02922777 (ASCO2022) Manual	Phase 1	Non-Small Cell Lung Cancer First line	21	Docetaxel+Bemcentinib	fhiebtjitt(cadlmlfqqx) = 60 mg/m2 docetaxel plus 200 mg bemcentinib daily kidujgwlbr (ieahwvdygn ) View more	Positive	02 Jun 2022
NCT02488408 (BGBC003, EHA2022) Manual	Phase 2	Acute Myeloid Leukemia	22	Cytarabine+Bemcentinib	hlnsrqrijy(tnphyzmdse) = ypxnxqfqdx slsqpebztx (mhoikefpxy ) View more	Positive	12 May 2022
				Cytarabine+Bemcentinib (in 1st relapse)	hlnsrqrijy(tnphyzmdse) = osbroxvkav slsqpebztx (mhoikefpxy ) View more
NCT04890509 (BGBIL019 \| ACCORD2, PRNewswire) Manual	Phase 2	COVID-19	61	Standard of Care+bemcentinib	fyoqpkaqjb(leqcnjtdaz) = lncuhjksqk mcatrxsezp (pmhnepqbte ) View more	Positive	26 Apr 2022
				Standard of Care	fyoqpkaqjb(leqcnjtdaz) = dwkfnjpuag mcatrxsezp (pmhnepqbte ) View more
NCT03184558 (CTgov)	Phase 2	Triple Negative Breast Cancer \| Metastatic breast cancer	29	Pembrolizumab+Bemcentinib	qkusqyobtb(fkcrtabqur) = rkwssrjhfn dtkhzbnuai (woagalsxhl, fzdaxijdvy - jspaxpbidb) View more	-	09 Nov 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis